Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients

• Published in: American journal of ophthalmology Vol. 238; pp. 173 - 180
• Main Authors: Maalouf, Georgina, Andrillon, Anaïs, Leclercq, Mathilde, Sève, Pascal, Bielefeld, Philip, Gueudry, Julie, Sené, Thomas, Titah, Cherif, Moulinet, Thomas, Rouvière, Bénédicte, Sène, Damien, Desbois, Anne-Claire, Domont, Fanny, Touhami, Sara, Thibault, Thomas, Chamieh, Carolla El, Cacoub, Patrice, Kodjikian, Laurent, Biard, Lucie, Bodaghi, Bahram, Saadoun, David
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2022; Elsevier Limited; Elsevier Masson
• Subjects: Adalimumab; Behcet Syndrome; Diabetic retinopathy; Disease control; Drug dosages; Ecology, environment; Edema; FDA approval; Health; Human health and pathology; Infectious diseases; Inflammation; Infliximab; Life Sciences; macular edema; Medical imaging; Microbiology and Parasitology; Monoclonal antibodies; Multivariate analysis; Patients; Relapse rate; Retinal vasculitis; Steroids; TNF inhibitors; Tumor necrosis factor-TNF; Uveitis; macular edema; Relapse rate; Infliximab; Adalimumab; Retinal vasculitis
• ISSN: 0002-9394; 1879-1891; 1879-1891
• DOI: 10.1016/j.ajo.2022.02.002

To compare the relapse rate of sight-threatening noninfectious uveitis (NIU) in patients treated with infliximab (IFX) or adalimumab (ADA). Observational retrospective multicenter study. A total of 330 patients (median age, 36 years; interquartile range, 27-54), 45.2% men) with sight-threatening NIU (ie, retinal vasculitis and/or macular edema) treated with anti−tumor necrosis factor [TNF]−α agents (IFX intravenously at 5 mg/kg at weeks 0, 2, 6, and every 4 to 6 weeks or ADA subcutaneously at 80 mg, then 40 mg every 2 weeks). Data were obtained retrospectively from patients’ medical records. Main outcome measures were relapse rate, complete response of NIU, corticosteroid sparing effect, and safety. Main etiologies of uveitis included Behçet disease (27%), idiopathic juvenile arthritis (5.8%), and sarcoidosis (5.5%). The estimated relapse rate at 6 months after introduction of biological agents was 13% (95% CI = 0.009-0.16). IFX was associated with less relapse risk than ADA (hazard ratio [HR] = 0.52, 95% CI = 0.36- 0.77, P = .001). ADA and IFX were comparable in terms of complete response rate of NIU as well as corticosteroid-sparing effect. Behçet disease was associated with higher odds of complete response (HR = 2.04, 95% CI = 1.16 -3.60, P = .01] and lower relapse rate (HR = 0.53, 95% CI = 0.33-0.85, P = .009) than other causes of NIU with anti−TNF-α agents. In sight-threatening NIU, IFX seems to be associated with a lower relapse rate than ADA.